Acinetobacter species represent a diverse and adaptable group of Gram-negative bacteria with clinical significance and environmental ubiquity. While the genus includes multiple species, Acinetobacter baumannii stands out as a major human pathogen, causing healthcare-associated infections worldwide. The bacteria exhibit intrinsic resistance to desiccation, allowing them to survive in various environments, including hospital surfaces and medical equipment. Acinetobacter baumannii infections commonly manifest as ventilator-associated pneumonia, bloodstream infections, and wound infections, particularly affecting individuals in intensive care units and those with underlying health conditions. The bacteria's remarkable ability to acquire resistance genes has led to the emergence of multidrug-resistant strains, posing a serious therapeutic challenge. Carbapenem-resistant Acinetobacter baumannii strains, in particular, limit treatment options and underscore the need for vigilant infection control practices. Preventive strategies involve rigorous infection control measures, antimicrobial stewardship, and surveillance to curb the spread of Acinetobacter species in healthcare settings. Research efforts are underway to decipher the genetic mechanisms of resistance and explore alternative treatment options, including phage therapy and novel antimicrobial agents, in the ongoing battle against infections caused by these resilient bacteria.